CompletedNCT07431476
Brimonidine 0.33% for Rosacea-Related Facial Erythema
Medication studyAges 18+TürkiyeAnxiety
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- IstanbulSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: May 1, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- Istanbul Training and Research Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Türkiye
- Age range
- Over 18 Years
- Official registry ID
- NCT07431476
- Official title
Show the full official title
Acute and Short-Term Efficacy of 0.33% Brimonidine in Persistent Erythema of Rosacea: A Prospective Two-Phase Study Incorporating a Split-Face, Randomized, Placebo-Controlled Design and Objective Biophysical and Dermoscopic Assessments
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Istanbul, Türkiye · Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Istanbul Training and Research Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Brimonidine 0.33% gel and Placebo gel.
Who was this study for?
Listed age limits: from 18 years.
